JP2016519068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519068A5 JP2016519068A5 JP2016502228A JP2016502228A JP2016519068A5 JP 2016519068 A5 JP2016519068 A5 JP 2016519068A5 JP 2016502228 A JP2016502228 A JP 2016502228A JP 2016502228 A JP2016502228 A JP 2016502228A JP 2016519068 A5 JP2016519068 A5 JP 2016519068A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cell
- region
- subject
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783445P | 2013-03-14 | 2013-03-14 | |
| US61/783,445 | 2013-03-14 | ||
| PCT/US2014/026734 WO2014151960A2 (en) | 2013-03-14 | 2014-03-13 | Methods for controlling t cell proliferation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018105044A Division JP2018145194A (ja) | 2013-03-14 | 2018-05-31 | Ｔ細胞増殖をコントロールするための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519068A JP2016519068A (ja) | 2016-06-30 |
| JP2016519068A5 true JP2016519068A5 (https=) | 2017-04-06 |
| JP6541639B2 JP6541639B2 (ja) | 2019-07-10 |
Family
ID=51569299
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502228A Active JP6541639B2 (ja) | 2013-03-14 | 2014-03-13 | Ｔ細胞増殖をコントロールするための方法 |
| JP2018105044A Withdrawn JP2018145194A (ja) | 2013-03-14 | 2018-05-31 | Ｔ細胞増殖をコントロールするための方法 |
| JP2019225565A Withdrawn JP2020055863A (ja) | 2013-03-14 | 2019-12-13 | Ｔ細胞増殖をコントロールするための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018105044A Withdrawn JP2018145194A (ja) | 2013-03-14 | 2018-05-31 | Ｔ細胞増殖をコントロールするための方法 |
| JP2019225565A Withdrawn JP2020055863A (ja) | 2013-03-14 | 2019-12-13 | Ｔ細胞増殖をコントロールするための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9944690B2 (https=) |
| EP (1) | EP2968502B1 (https=) |
| JP (3) | JP6541639B2 (https=) |
| KR (1) | KR20150131218A (https=) |
| CN (1) | CN105209065B (https=) |
| AU (2) | AU2014236726A1 (https=) |
| CA (1) | CA2905352A1 (https=) |
| HK (1) | HK1217000A1 (https=) |
| SG (1) | SG11201506974XA (https=) |
| WO (1) | WO2014151960A2 (https=) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2516320C (en) | 2003-02-18 | 2015-05-26 | Kevin Slawin | Induced activation in dendritic cells |
| EP2331680B1 (en) | 2008-09-22 | 2017-05-03 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| EP4303232A3 (en) | 2013-02-15 | 2024-04-17 | The Regents of The University of California | Chimeric antigen receptor and methods of use thereof |
| WO2014151960A2 (en) * | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| AU2014240083C1 (en) | 2013-03-15 | 2019-10-24 | Celgene Corporation | Modified T lymphocytes |
| US10934346B2 (en) * | 2014-02-14 | 2021-03-02 | Bellicum Pharmaceuticals, Inc. | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 |
| AU2015244039B2 (en) | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| US10888608B2 (en) | 2014-09-02 | 2021-01-12 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides |
| KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
| ES2904301T3 (es) | 2014-11-03 | 2022-04-04 | Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum | Receptores de células T dirigidos contra Bob1 y usos de los mismos |
| HK1245827B (en) * | 2014-12-15 | 2020-06-19 | Board Of Regents Of The University Of Texas System | Methods for controlled activation or elimination of therapeutic cells |
| CA2966234A1 (en) * | 2014-12-15 | 2016-06-23 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| CA3197849A1 (en) | 2014-12-29 | 2016-07-07 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US10377988B2 (en) | 2015-01-23 | 2019-08-13 | Musc Foundation For Research Development | Cytokine receptor genes and the use thereof to enhance therapy |
| JP7264592B2 (ja) | 2015-01-26 | 2023-04-25 | ザ ユニバーシティー オブ シカゴ | ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用 |
| WO2016123143A1 (en) | 2015-01-26 | 2016-08-04 | The University Of Chicago | CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2 |
| ES2869972T3 (es) | 2015-01-26 | 2021-10-26 | Cellectis | Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas |
| WO2016138034A1 (en) | 2015-02-24 | 2016-09-01 | The Regents Of The University Of California | Binding-triggered transcriptional switches and methods of use thereof |
| WO2016149254A1 (en) * | 2015-03-17 | 2016-09-22 | Chimera Bioengineering, Inc. | Smart car devices, de car polypeptides, side cars and uses thereof |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| SG11201708516YA (en) | 2015-04-17 | 2017-11-29 | David Maxwell Barrett | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| AU2016297014B2 (en) | 2015-07-21 | 2021-06-17 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
| US11649435B2 (en) | 2015-08-28 | 2023-05-16 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| WO2017040324A1 (en) | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| JP6905163B2 (ja) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
| US12533338B2 (en) * | 2015-09-30 | 2026-01-27 | Vycellix, Inc. | Enhanced gene delivery to natural killer cells, hematopoietic stem cells and macrophages |
| US10954500B2 (en) | 2015-10-23 | 2021-03-23 | Fred Hutchinson Cancer Research Center | Methods to create chemically-induced dimerizing protein systems for regulation of cellular events |
| MX2018005618A (es) * | 2015-11-05 | 2018-08-01 | Juno Therapeutics Inc | Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados. |
| US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| JP2019506143A (ja) * | 2015-12-14 | 2019-03-07 | ベリカム ファーマシューティカルズ， インコーポレイテッド | 治療用細胞の活性化及び排除のための二重コントロール |
| SG11201805449PA (en) | 2015-12-28 | 2018-07-30 | Novartis Ag | Methods of making chimeric antigen receptor -expressing cells |
| JP7068169B2 (ja) | 2016-01-08 | 2022-05-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 条件付活性ヘテロ二量体ポリペプチド及びその使用方法 |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| CN109414455B (zh) | 2016-04-01 | 2023-01-20 | 凯德药业股份有限公司 | Bcma结合分子及其使用方法 |
| KR20200068750A (ko) | 2016-04-01 | 2020-06-15 | 카이트 파마 인코포레이티드 | 키메라 수용체 및 그의 사용 방법 |
| PT3436079T (pt) | 2016-04-01 | 2021-10-06 | Kite Pharma Inc | Recetores de antigénios quiméricos e de células t e métodos de uso |
| MY210545A (en) | 2016-04-01 | 2025-09-30 | Kite Pharma Inc | Chimeric receptors to flt3 and methods of use thereof |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| EP3458077A4 (en) | 2016-05-17 | 2020-04-01 | Chimera Bioengineering Inc. | METHODS OF MANUFACTURING NEW AREAS OF ANTIGEN BINDING |
| US20210177896A1 (en) | 2016-06-02 | 2021-06-17 | Novartis Ag | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
| US11384156B2 (en) * | 2016-07-25 | 2022-07-12 | The Nemours Foundation | Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases |
| EP4342978A3 (en) | 2016-09-01 | 2024-07-03 | Chimera Bioengineering Inc. | Gold optimized car t-cells |
| EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| BR102018006205A2 (pt) * | 2017-03-28 | 2021-03-23 | Cell Design Labs, Inc. | Polipeptídeos quiméricos e métodos de alterar a localização da membrana dos mesmos |
| ES2894106T3 (es) * | 2017-04-21 | 2022-02-11 | Safe Implant Tech Aps | Partículas de oro para su uso en la terapia para prevenir o reducir la contractura capsular |
| SG10201912400VA (en) | 2017-04-24 | 2020-02-27 | Kite Pharma Inc | Humanized antigen-binding domains against cd19 and methods of use |
| WO2018208849A1 (en) | 2017-05-09 | 2018-11-15 | Bellicum Pharmaceuticals, Inc. | Methods to augment or alter signal transduction |
| EP3624811A4 (en) | 2017-05-19 | 2021-03-10 | The Regents of The University of California | ANTIBODY-BASED CHEMICAL INDUCED DIMERIZER (ABCID) AS A MOLECULAR SWITCH FOR REGULATING CELL THERAPIES |
| TWI731268B (zh) * | 2017-09-29 | 2021-06-21 | 財團法人國家衛生研究院 | 可增強抗腫瘤與抗病毒ｔ細胞存活與其功能性之方法與組合物 |
| MX2020004229A (es) | 2017-10-25 | 2020-07-22 | Novartis Ag | Metodos de produccion de celulas que expresan receptores antigenicos quimericos. |
| WO2019099707A1 (en) | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
| EP3720479A2 (en) | 2017-12-08 | 2020-10-14 | Bellicum Pharmaceuticals, Inc. | Methods for enhancing and maintaining car-t cell efficacy |
| WO2019126344A1 (en) | 2017-12-20 | 2019-06-27 | Bellicum Pharmaceuticals, Inc. | Multimeric piperidine derivatives |
| AU2018396083B2 (en) | 2017-12-29 | 2025-09-25 | Cellectis | Method for improving production of CAR T cells |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CN111989108B (zh) | 2018-02-13 | 2024-07-16 | 嵌合体生物工程公司 | 利用rna去稳定元件协调基因表达 |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| WO2019169290A1 (en) | 2018-03-02 | 2019-09-06 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| CA3095920A1 (en) | 2018-04-10 | 2019-10-17 | Amgen Inc. | Chimeric receptors to dll3 and methods of use thereof |
| US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
| EA202190304A1 (ru) | 2018-07-18 | 2022-01-21 | Эмджен Инк. | Химерные рецепторы к steap1 и способы их применения |
| CN113474450A (zh) | 2018-08-09 | 2021-10-01 | 朱诺治疗学股份有限公司 | 产生工程化细胞的方法以及所述工程化细胞的组合物 |
| WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| CA3109959A1 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2020069409A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
| EP3856779A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd22 chimeric antigen receptor (car) therapies |
| KR102840400B1 (ko) | 2018-12-12 | 2025-08-04 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
| EP3931208A1 (en) | 2019-03-01 | 2022-01-05 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
| BR112021017365A2 (pt) | 2019-03-01 | 2022-02-01 | Allogene Therapeutics Inc | Receptores de citocina quiméricos constitutivamente ativos |
| WO2020180591A1 (en) | 2019-03-01 | 2020-09-10 | Allogene Therapeutics, Inc. | Dll3 targeting chimeric antigen receptors and binding agents |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| JP7664180B2 (ja) | 2019-04-26 | 2025-04-17 | アロジーン セラピューティクス，インコーポレイテッド | リツキシマブ耐性キメラ抗原受容体およびその用途 |
| KR20220004028A (ko) | 2019-04-26 | 2022-01-11 | 알로젠 테라퓨틱스 인코포레이티드 | 동종 car t 세포를 제조하는 방법 |
| EP3962519A1 (en) | 2019-05-01 | 2022-03-09 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
| AU2020265741A1 (en) | 2019-05-01 | 2021-11-25 | Editas Medicine, Inc. | Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods |
| JP2019170393A (ja) * | 2019-06-19 | 2019-10-10 | 国立大学法人九州大学 | ｉＰＳ細胞の作製方法 |
| EP4013431A4 (en) | 2019-08-18 | 2024-05-01 | Chimera Bioengineering, Inc. | Combination therapy with gold controlled transgenes |
| WO2021041806A1 (en) | 2019-08-30 | 2021-03-04 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising tgf beta binding domains |
| AU2021217003A1 (en) | 2020-02-04 | 2022-09-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-dinitrophenol chimeric antigen receptors |
| EP4104187A1 (en) | 2020-02-14 | 2022-12-21 | Novartis AG | Method of predicting response to chimeric antigen receptor therapy |
| JP2023514407A (ja) | 2020-02-24 | 2023-04-05 | アロジーン セラピューティクス，インコーポレイテッド | 増強された活性を有するｂｃｍａ ｃａｒ－ｔ細胞 |
| KR20220146530A (ko) | 2020-02-27 | 2022-11-01 | 노파르티스 아게 | 키메라 항원 수용체-발현 세포의 제조 방법 |
| EP4171616A1 (en) | 2020-06-26 | 2023-05-03 | Juno Therapeutics GmbH | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| EP4175650A1 (en) | 2020-07-06 | 2023-05-10 | Kiromic BioPharma, Inc. | Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof |
| AU2021308702A1 (en) | 2020-07-17 | 2023-03-16 | Instil Bio (Uk) Limited | Receptors providing targeted costimulation for adoptive cell therapy |
| KR20230107617A (ko) | 2020-11-13 | 2023-07-17 | 노파르티스 아게 | 키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법 |
| CA3202233A1 (en) | 2020-11-18 | 2022-05-27 | Kiromic BioPharma, Inc. | Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules |
| WO2022115492A1 (en) | 2020-11-24 | 2022-06-02 | Lyell Immunopharma, Inc. | Methods for making, compositions comprising, and methods of using rejuvenated t cells |
| WO2022140388A1 (en) | 2020-12-21 | 2022-06-30 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
| EP4355340A4 (en) | 2021-06-16 | 2025-05-21 | Instil Bio, Inc. | RECEPTORS FOR TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY |
| EP4370213A4 (en) | 2021-07-16 | 2025-06-04 | Instil Bio (Uk) Limited | Chimeric molecules for targeted costimulation for adoptive cell therapy |
| WO2023009989A1 (en) | 2021-07-26 | 2023-02-02 | Kite Pharma, Inc. | Split chimeric antigen receptors and methods of use |
| US12576135B2 (en) | 2021-09-29 | 2026-03-17 | Chimera Bioengineering, Inc. | Compositions and methods for anti-TnMUC1 gold CAR t-cells |
| CN114410689B (zh) * | 2022-03-29 | 2022-06-17 | 北京循生生物医学研究有限公司 | 一种增强肿瘤浸润淋巴细胞杀伤力的制备方法 |
| EP4587047A1 (en) | 2022-09-15 | 2025-07-23 | Novartis AG | Treatment of autoimmune disorders using chimeric antigen receptor therapy |
| TW202440623A (zh) | 2022-11-28 | 2024-10-16 | 美商艾洛基因醫療公司 | 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途 |
| CN116179495B (zh) * | 2022-11-28 | 2025-06-06 | 上海恩凯细胞技术有限公司 | 转基因免疫细胞及其应用 |
| WO2024182539A1 (en) | 2023-02-28 | 2024-09-06 | Lyell Immunopharma, Inc. | Methods of culturing reprogrammed cells |
| KR20260013442A (ko) * | 2023-03-17 | 2026-01-28 | 카티전 테라퓨틱스, 인코포레이티드 | 키메라 항원 수용체의 장기 발현을 위해 조정된 세포내 신호전달 및 공동자극 도메인 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4514506A (en) | 1982-02-23 | 1985-04-30 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens |
| EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
| FR2610631B1 (fr) | 1987-02-09 | 1989-11-24 | Pasteur Institut | Molecules comportant au moins une sequence peptidique porteuse d'un ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum dans les hepatocytes, et leurs utilisations, notamment pour le diagnostic du paludisme ou dans des compositions de vaccins contre le paludisme |
| US5869608A (en) | 1989-03-17 | 1999-02-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis |
| US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| CA2067031C (en) | 1991-04-26 | 2003-02-18 | Shigekazu Nagata | Dna coding for human cell surface antigen |
| US5780036A (en) | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
| US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| CZ206195A3 (en) | 1993-02-12 | 1996-04-17 | Univ Leland Stanford Junior | Controlled transcription of target genes and other biological materials |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US5426027A (en) | 1993-05-20 | 1995-06-20 | The Government Of The United States Of America As Represented By The Secretary | Nucleic acid probes and methods for detecting Candida DNA cells in blood |
| US5648226A (en) | 1993-07-22 | 1997-07-15 | Ludwig Institute For Cancer Research | Isolated peptides derived from tumor rejection antigens, and their use |
| JPH09502086A (ja) | 1993-08-06 | 1997-03-04 | サイテル コーポレイション | 完全ｍａｇｅ１遺伝子のクローニング及び特性決定 |
| US5550214A (en) | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
| US5709995A (en) | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| JPH11511643A (ja) | 1994-10-25 | 1999-10-12 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・リランド・スタンフォード・ジュニア・ユニバーシティ | 遺伝子工学処理された細胞の条件的形質転換 |
| US6077947A (en) | 1995-02-02 | 2000-06-20 | Cell Genesys, Inc. | DNA encoding an intracellular chimeric receptor comprising Janus kinase |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| NZ333607A (en) | 1996-07-10 | 2000-08-25 | Immunex Corp | Method of stimulating the immune system by transfecting dendritic cells |
| US5955596A (en) | 1996-07-26 | 1999-09-21 | American Cyanamid Company | NucA protein of Haemophilus influenzae and the gene encoding that protein |
| US6046158A (en) | 1996-12-20 | 2000-04-04 | Board Of Regents The University Of Texas Systems | Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof |
| US5965242A (en) | 1997-02-19 | 1999-10-12 | Eastman Kodak Company | Glow-in-the-dark medium and method of making |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| US6558951B1 (en) | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| GB9930616D0 (en) | 1999-12-24 | 2000-02-16 | Mathilda & Terence Kennedy Ins | Activation and inhibition of the immune system |
| EP1254953A4 (en) | 1999-12-28 | 2004-06-02 | Toyoshima Kumao | Maturity-triggering agent for immature dendritic cells |
| US7435585B2 (en) | 2000-01-03 | 2008-10-14 | University Of Pennsylvania | Auto-stimulating cells and methods for making and using the same |
| SE0001642D0 (sv) | 2000-05-04 | 2000-05-04 | Sahltech Ab | Reagent for detection of biomolecules, and use thereof |
| US20030232055A1 (en) | 2000-07-31 | 2003-12-18 | Ruslan Medzhitov | Innate immune system-directed vaccines |
| AU2001281252A1 (en) | 2000-08-10 | 2002-02-18 | Board Of Regents, The University Of Texas System | The tumor suppressor car-1 |
| US7666424B2 (en) * | 2001-10-17 | 2010-02-23 | Sloan-Kettering Institute For Cancer Research | Methods of preparing and using single chain anti-tumor antibodies |
| AU2002221780A1 (en) | 2000-10-31 | 2002-05-15 | F.Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| US6965023B2 (en) | 2000-11-17 | 2005-11-15 | The Burnham Institute | Death domain proteins |
| WO2003006606A2 (en) | 2001-07-09 | 2003-01-23 | Oklahoma Medical Research Foundation | Targeted fusion proteins and methods for the characterization of cellular membrane domains |
| US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
| JP4360906B2 (ja) | 2001-09-14 | 2009-11-11 | サイトス バイオテクノロジー アーゲー | ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化 |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| AU2002353890A1 (en) | 2001-10-26 | 2003-05-06 | Cleveland Clinic Foundation | Fused cells, methods of forming same, and therapie utilizing same |
| GB0225279D0 (en) | 2002-10-30 | 2002-12-11 | Celltech R&D Ltd | Biological products |
| CA2516320C (en) | 2003-02-18 | 2015-05-26 | Kevin Slawin | Induced activation in dendritic cells |
| US20050113564A1 (en) * | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| WO2007050095A2 (en) | 2004-11-19 | 2007-05-03 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
| US8088908B2 (en) | 2005-05-10 | 2012-01-03 | City Of Hope | Humanized anti-prostate stem cell antigen monoclonal antibody |
| KR100705981B1 (ko) | 2005-10-12 | 2007-04-10 | 주식회사 리제론 | 인간 성장호르몬을 포함하는 탈모방지 또는 발모촉진용조성물 |
| US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| US20100105136A1 (en) * | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| CA2666667C (en) | 2006-10-19 | 2023-06-20 | Baylor College Of Medicine | Generating an immune response by inducing cd40 and pattern recognition receptors |
| NZ599777A (en) | 2007-11-07 | 2013-09-27 | Celldex Therapeutics Inc | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| US8114968B2 (en) | 2008-03-03 | 2012-02-14 | Dyax Corp. | Metalloproteinase-12 specific monoclonal antibody |
| EP4032552B1 (en) * | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| EP2331680B1 (en) * | 2008-09-22 | 2017-05-03 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters |
| AU2011239569B2 (en) | 2010-04-16 | 2014-07-24 | Baylor College Of Medicine | Method for treating solid tumors |
| WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| ES2791716T3 (es) * | 2010-12-14 | 2020-11-05 | Univ Maryland | Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer |
| WO2012127464A2 (en) | 2011-03-23 | 2012-09-27 | Gavish-Galilee Bio Applications Ltd | Constitutively activated t cells for use in adoptive cell therapy |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| EP3692794A1 (en) * | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| WO2013067492A1 (en) * | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| WO2013078433A1 (en) | 2011-11-23 | 2013-05-30 | University Of Hawaii | Auto-processing domains for polypeptide expression |
| WO2013126720A2 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing |
| EA033110B1 (ru) | 2012-04-11 | 2019-08-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы |
| US20130280220A1 (en) * | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| AU2013255511B2 (en) | 2012-05-04 | 2016-01-28 | Pfizer Inc. | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| KR102437522B1 (ko) * | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| EP2906684B8 (en) * | 2012-10-10 | 2020-09-02 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| EP4303232A3 (en) | 2013-02-15 | 2024-04-17 | The Regents of The University of California | Chimeric antigen receptor and methods of use thereof |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| WO2014151960A2 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| CA2912172A1 (en) | 2013-06-05 | 2014-12-11 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| US10934346B2 (en) | 2014-02-14 | 2021-03-02 | Bellicum Pharmaceuticals, Inc. | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 |
| CA2940460A1 (en) | 2014-03-07 | 2015-09-11 | Bellicum Pharmaceuticals, Inc. | Caspase polypeptides having modified activity and uses thereof |
| US10888608B2 (en) | 2014-09-02 | 2021-01-12 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides |
-
2014
- 2014-03-13 WO PCT/US2014/026734 patent/WO2014151960A2/en not_active Ceased
- 2014-03-13 EP EP14770399.5A patent/EP2968502B1/en active Active
- 2014-03-13 AU AU2014236726A patent/AU2014236726A1/en not_active Abandoned
- 2014-03-13 SG SG11201506974XA patent/SG11201506974XA/en unknown
- 2014-03-13 CA CA2905352A patent/CA2905352A1/en not_active Abandoned
- 2014-03-13 CN CN201480028439.3A patent/CN105209065B/zh active Active
- 2014-03-13 US US14/210,034 patent/US9944690B2/en active Active
- 2014-03-13 HK HK16105044.7A patent/HK1217000A1/zh unknown
- 2014-03-13 KR KR1020157028844A patent/KR20150131218A/ko not_active Ceased
- 2014-03-13 JP JP2016502228A patent/JP6541639B2/ja active Active
-
2018
- 2018-03-02 US US15/910,380 patent/US20180265566A1/en not_active Abandoned
- 2018-05-31 JP JP2018105044A patent/JP2018145194A/ja not_active Withdrawn
-
2019
- 2019-03-07 AU AU2019201586A patent/AU2019201586A1/en not_active Abandoned
- 2019-12-13 JP JP2019225565A patent/JP2020055863A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519068A5 (https=) | ||
| US20240417481A1 (en) | Bcma chimeric antigen receptors | |
| Weinkove et al. | Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations | |
| AU2018203687B2 (en) | Improved methods for manufacturing adoptive cell therapies | |
| JP2023178438A (ja) | Ｂｃｍａキメラ抗原受容体 | |
| AU2014259675B2 (en) | CS1-specific chimeric antigen receptor engineered immune effector cells | |
| JP7288503B2 (ja) | 改変された抗ｃｄ１９ ｃａｒ－ｔ細胞 | |
| JP2016521709A5 (https=) | ||
| JP2018501786A5 (https=) | ||
| RS62733B1 (sr) | Mnd promoter himernih antigenskih receptora | |
| JP2019525898A (ja) | ヒト白血球抗原拘束ガンマデルタｔ細胞受容体及びその使用方法 | |
| CN108137670A (zh) | Ny-eso-1特异性tcr及其使用方法 | |
| US20240101616A1 (en) | Dap10/12 based cars adapted for rush | |
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| US20230192848A1 (en) | Engineered cell compositions and methods of use thereof | |
| KR20250005572A (ko) | Cd4 특이적 항체 작제물과 조성물 및 이의 용도 | |
| KR20250111218A (ko) | 혈액학적 암의 치료에 사용하기 위한 키트 | |
| JP2025512407A (ja) | Ｃｍｖ－ｈｉｖ特異的キメラ抗原受容体ｔ細胞 | |
| WO2023190550A1 (ja) | 遺伝子改変免疫細胞療法のための選択的制御遺伝子（ｓｒｇ）システム | |
| EA045264B1 (ru) | Способ лечения гемобластоза с помощью иммунных эффекторных клеток, содержащих химерные антигенные рецепторы к bcma | |
| BR112017001498B1 (pt) | Receptor de antígeno quimérico (car) anti-bcma, polinucleotídeo que codifica o dito car, vetor, composição e uso da mesma para tratar uma condição relacionada à célula b |